Untreated CML cases, on average, carry a 2-3 year survival period.
There is a 70-90% response rate to a newer drug called "Imatinib”. Imatinib targets the product of the bcr/abl fusion, namely the tyrosine kinase. Those who respond to Imatinib have up to 5 years with no disease progression.
Allogeneic stem cell transplant is an option for those that fail to respond to Imatinib treatment.
3. “Mechanism Imatinib.svg.” Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Mechanism_imatinib.svg.
